About Mirabegron (Alpha) API
Therapeutic CategoryUrology
CAS Number
223673-61-8
API Technology
Synthetic
Dose Form
ER Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Canada DMF, Korea DMF, China DMF, CEP Submitted
Mechanism of Action
Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR. Mirabegron relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 AR which increases bladder capacity. Although mirabegron showed very low intrinsic activity for cloned human beta-1 AR and beta-2 AR, results in humans indicate that beta-1 AR stimulation occurred at a mirabegron dose of 200 mg.
Indication
MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
MYRBETRIQ, in combination with the muscarinic antagonist solifenacin succinate, is indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency
Related APIs
Dutasteride
Urology
Mirabegron (Alpha)
Urology
Testosterone
Urology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
FAQs
Treats overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency
-
Increases bladder capacity
Reduces urgency and frequency of urination
Improves quality of life for OAB patients
-
Monitor blood pressure regularly
Avoid in patients with severe uncontrolled hypertension
Use protective equipment when handling
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.